These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 21162599)

  • 1. Disease registries and outcomes research in children: focus on lysosomal storage disorders.
    Jones S; James E; Prasad S
    Paediatr Drugs; 2011 Feb; 13(1):33-47. PubMed ID: 21162599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders.
    Hollak CE; Aerts JM; Aymé S; Manuel J
    Orphanet J Rare Dis; 2011 Apr; 6():16. PubMed ID: 21496291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare lysosomal disease registries: lessons learned over three decades of real-world evidence.
    Mistry PK; Kishnani P; Wanner C; Dong D; Bender J; Batista JL; Foster J
    Orphanet J Rare Dis; 2022 Oct; 17(1):362. PubMed ID: 36244992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
    Mechler K; Mountford WK; Hoffmann GF; Ries M
    Orphanet J Rare Dis; 2015 Apr; 10():46. PubMed ID: 25896727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA orphan drug designations for lysosomal storage disorders - a cross-sectional analysis.
    Garbade SF; Zielonka M; Mechler K; Kölker S; Hoffmann GF; Staufner C; Mengel E; Ries M
    PLoS One; 2020; 15(4):e0230898. PubMed ID: 32267884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
    Maier WC; Christensen RA; Anderson P
    Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emptying the stores: lysosomal diseases and therapeutic strategies.
    Platt FM
    Nat Rev Drug Discov; 2018 Feb; 17(2):133-150. PubMed ID: 29147032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical studies in lysosomal storage diseases: past, present and future.
    Boudes PF
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():68-76. PubMed ID: 24380125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs for lysosomal storage diseases.
    Beck M
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):495-507. PubMed ID: 20557271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Astrocytes and lysosomal storage diseases.
    Rama Rao KV; Kielian T
    Neuroscience; 2016 May; 323():195-206. PubMed ID: 26037807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare disease registries: potential applications towards impact on development of new drug treatments.
    Jansen-van der Weide MC; Gaasterland CMW; Roes KCB; Pontes C; Vives R; Sancho A; Nikolakopoulos S; Vermeulen E; van der Lee JH
    Orphanet J Rare Dis; 2018 Sep; 13(1):154. PubMed ID: 30185208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical studies in lysosomal storage diseases: Past, present, and future.
    Boudes PF
    Rare Dis; 2013; 1():e26690. PubMed ID: 25003011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders.
    Mulberg AE; Bucci-Rechtweg C; Giuliano J; Jacoby D; Johnson FK; Liu Q; Marsden D; McGoohan S; Nelson R; Patel N; Romero K; Sinha V; Sitaraman S; Spaltro J; Kessler V
    Orphanet J Rare Dis; 2019 Feb; 14(1):36. PubMed ID: 30736861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten plus one challenges in diseases of the lysosomal system.
    Grabowski GA; Whitley C
    Mol Genet Metab; 2017; 120(1-2):38-46. PubMed ID: 27923545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Infrastructure for new drug development to treat muscular dystrophy: current status of patient registration (remudy)].
    Nakamura H; Kimura E; Kawai M
    Brain Nerve; 2011 Nov; 63(11):1279-84. PubMed ID: 22068481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurological manifestations in lysosomal storage disorders - from pathology to first therapeutic possibilities.
    Hoffmann B; Mayatepek E
    Neuropediatrics; 2005 Oct; 36(5):285-9. PubMed ID: 16217702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rare partnership: patient community and industry collaboration to shape the impact of real-world evidence on the rare disease ecosystem.
    Klein TL; Bender J; Bolton S; Collin-Histed T; Daher A; De Baere L; Dong D; Hopkin J; Johnson J; Lai T; Pavlou M; Schaller T; Žnidar I
    Orphanet J Rare Dis; 2024 Jul; 19(1):262. PubMed ID: 38987844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the quality of healthcare provided to children.
    Mangione-Smith R; McGlynn EA
    Health Serv Res; 1998 Oct; 33(4 Pt 2):1059-90. PubMed ID: 9776949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.